VIRBAC SA (VIRP.PA) Stock Fundamental Analysis

EPA:VIRP • FR0000031577

367 EUR
0 (0%)
Last: Feb 20, 2026, 10:47 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

Taking everything into account, VIRP scores 5 out of 10 in our fundamental rating. VIRP was compared to 52 industry peers in the Pharmaceuticals industry. VIRP has only an average score on both its financial health and profitability. VIRP has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year VIRP was profitable.
  • In the past year VIRP had a positive cash flow from operations.
  • Each year in the past 5 years VIRP has been profitable.
  • In the past 5 years VIRP always reported a positive cash flow from operatings.
VIRP.PA Yearly Net Income VS EBIT VS OCF VS FCFVIRP.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

1.2 Ratios

  • The Return On Assets of VIRP (8.00%) is better than 61.54% of its industry peers.
  • VIRP has a Return On Equity (13.64%) which is in line with its industry peers.
  • The Return On Invested Capital of VIRP (11.47%) is comparable to the rest of the industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for VIRP is below the industry average of 14.45%.
Industry RankSector Rank
ROA 8%
ROE 13.64%
ROIC 11.47%
ROA(3y)8.45%
ROA(5y)9.4%
ROE(3y)13.98%
ROE(5y)15.89%
ROIC(3y)12.4%
ROIC(5y)12.39%
VIRP.PA Yearly ROA, ROE, ROICVIRP.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15 20

1.3 Margins

  • VIRP has a Profit Margin of 10.40%. This is comparable to the rest of the industry: VIRP outperforms 44.23% of its industry peers.
  • In the last couple of years the Profit Margin of VIRP has grown nicely.
  • With a Operating Margin value of 16.39%, VIRP perfoms like the industry average, outperforming 44.23% of the companies in the same industry.
  • VIRP's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 67.10%, VIRP is in line with its industry, outperforming 40.38% of the companies in the same industry.
  • In the last couple of years the Gross Margin of VIRP has grown nicely.
Industry RankSector Rank
OM 16.39%
PM (TTM) 10.4%
GM 67.1%
OM growth 3Y1%
OM growth 5Y7.93%
PM growth 3Y-0.75%
PM growth 5Y13.61%
GM growth 3Y12.2%
GM growth 5Y6.39%
VIRP.PA Yearly Profit, Operating, Gross MarginsVIRP.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so VIRP is still creating some value.
  • VIRP has about the same amout of shares outstanding than it did 1 year ago.
  • VIRP has less shares outstanding than it did 5 years ago.
  • VIRP has a worse debt/assets ratio than last year.
VIRP.PA Yearly Shares OutstandingVIRP.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
VIRP.PA Yearly Total Debt VS Total AssetsVIRP.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 4.79 indicates that VIRP is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 4.79, VIRP is doing good in the industry, outperforming 67.31% of the companies in the same industry.
  • The Debt to FCF ratio of VIRP is 3.62, which is a good value as it means it would take VIRP, 3.62 years of fcf income to pay off all of its debts.
  • VIRP has a Debt to FCF ratio of 3.62. This is in the better half of the industry: VIRP outperforms 63.46% of its industry peers.
  • VIRP has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of VIRP (0.22) is better than 71.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF 3.62
Altman-Z 4.79
ROIC/WACC1.46
WACC7.88%
VIRP.PA Yearly LT Debt VS Equity VS FCFVIRP.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.3 Liquidity

  • VIRP has a Current Ratio of 1.96. This is a normal value and indicates that VIRP is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of VIRP (1.96) is better than 69.23% of its industry peers.
  • A Quick Ratio of 1.04 indicates that VIRP should not have too much problems paying its short term obligations.
  • With a decent Quick ratio value of 1.04, VIRP is doing good in the industry, outperforming 61.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.04
VIRP.PA Yearly Current Assets VS Current LiabilitesVIRP.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 20.61% over the past year.
  • The Earnings Per Share has been growing by 23.20% on average over the past years. This is a very strong growth
  • Looking at the last year, VIRP shows a quite strong growth in Revenue. The Revenue has grown by 12.07% in the last year.
  • VIRP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.29% yearly.
EPS 1Y (TTM)20.61%
EPS 3Y8.97%
EPS 5Y23.2%
EPS Q2Q%-12.92%
Revenue 1Y (TTM)12.07%
Revenue growth 3Y9.51%
Revenue growth 5Y8.29%
Sales Q2Q%5.03%

3.2 Future

  • Based on estimates for the next years, VIRP will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.81% on average per year.
  • Based on estimates for the next years, VIRP will show a small growth in Revenue. The Revenue will grow by 5.01% on average per year.
EPS Next Y3.92%
EPS Next 2Y7.82%
EPS Next 3Y8.79%
EPS Next 5Y10.81%
Revenue Next Year4.62%
Revenue Next 2Y5.05%
Revenue Next 3Y5.21%
Revenue Next 5Y5.01%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
VIRP.PA Yearly Revenue VS EstimatesVIRP.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
VIRP.PA Yearly EPS VS EstimatesVIRP.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 5 10 15 20 25

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 21.16 indicates a rather expensive valuation of VIRP.
  • VIRP's Price/Earnings ratio is in line with the industry average.
  • When comparing the Price/Earnings ratio of VIRP to the average of the S&P500 Index (27.09), we can say VIRP is valued slightly cheaper.
  • Based on the Price/Forward Earnings ratio of 17.26, the valuation of VIRP can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of VIRP indicates a somewhat cheap valuation: VIRP is cheaper than 65.38% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.98, VIRP is valued a bit cheaper.
Industry RankSector Rank
PE 21.16
Fwd PE 17.26
VIRP.PA Price Earnings VS Forward Price EarningsVIRP.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 71.15% of the companies in the same industry are more expensive than VIRP, based on the Enterprise Value to EBITDA ratio.
  • VIRP's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 34.29
EV/EBITDA 11.16
VIRP.PA Per share dataVIRP.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of VIRP may justify a higher PE ratio.
PEG (NY)5.4
PEG (5Y)0.91
EPS Next 2Y7.82%
EPS Next 3Y8.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

2

5. Dividend

5.1 Amount

  • VIRP has a yearly dividend return of 0.41%, which is pretty low.
  • Compared to an average industry Dividend Yield of 1.91, VIRP has a dividend in line with its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.85, VIRP's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.41%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years4
VIRP.PA Yearly Dividends per shareVIRP.PA Yearly Dividends per shareYearly Dividends per share 2021 2022 2023 2024 2025 0.5 1

5.3 Sustainability

  • VIRP pays out 8.36% of its income as dividend. This is a sustainable payout ratio.
DP8.36%
EPS Next 2Y7.82%
EPS Next 3Y8.79%
VIRP.PA Yearly Income VS Free CF VS DividendVIRP.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M
VIRP.PA Dividend Payout.VIRP.PA Dividend Payout, showing the Payout Ratio.VIRP.PA Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

VIRBAC SA

EPA:VIRP (2/20/2026, 10:47:25 AM)

367

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-16
Earnings (Next)03-17
Inst Owners25.28%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap3.08B
Revenue(TTM)1.40B
Net Income(TTM)145.29M
Analysts82.5
Price Target415.03 (13.09%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.41%
Yearly Dividend1.32
Dividend Growth(5Y)N/A
DP8.36%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.22%
PT rev (3m)2.91%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.01%
EPS NY rev (3m)-0.01%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 21.16
Fwd PE 17.26
P/S 2.2
P/FCF 34.29
P/OCF 15.66
P/B 2.89
P/tB 5.35
EV/EBITDA 11.16
EPS(TTM)17.34
EY4.72%
EPS(NY)21.26
Fwd EY5.79%
FCF(TTM)10.7
FCFY2.92%
OCF(TTM)23.44
OCFY6.39%
SpS166.55
BVpS126.95
TBVpS68.53
PEG (NY)5.4
PEG (5Y)0.91
Graham Number222.55
Profitability
Industry RankSector Rank
ROA 8%
ROE 13.64%
ROCE 16.54%
ROIC 11.47%
ROICexc 12.64%
ROICexgc 20.66%
OM 16.39%
PM (TTM) 10.4%
GM 67.1%
FCFM 6.43%
ROA(3y)8.45%
ROA(5y)9.4%
ROE(3y)13.98%
ROE(5y)15.89%
ROIC(3y)12.4%
ROIC(5y)12.39%
ROICexc(3y)14.41%
ROICexc(5y)15%
ROICexgc(3y)23.78%
ROICexgc(5y)25.77%
ROCE(3y)17.85%
ROCE(5y)17.84%
ROICexgc growth 3Y-15.04%
ROICexgc growth 5Y-5.22%
ROICexc growth 3Y-12.77%
ROICexc growth 5Y7.18%
OM growth 3Y1%
OM growth 5Y7.93%
PM growth 3Y-0.75%
PM growth 5Y13.61%
GM growth 3Y12.2%
GM growth 5Y6.39%
F-Score7
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF 3.62
Debt/EBITDA 0.8
Cap/Depr 166.76%
Cap/Sales 7.65%
Interest Coverage 45.52
Cash Conversion 67.09%
Profit Quality 61.8%
Current Ratio 1.96
Quick Ratio 1.04
Altman-Z 4.79
F-Score7
WACC7.88%
ROIC/WACC1.46
Cap/Depr(3y)125.08%
Cap/Depr(5y)109.34%
Cap/Sales(3y)4.99%
Cap/Sales(5y)4.5%
Profit Quality(3y)72.36%
Profit Quality(5y)71.26%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y8.97%
EPS 5Y23.2%
EPS Q2Q%-12.92%
EPS Next Y3.92%
EPS Next 2Y7.82%
EPS Next 3Y8.79%
EPS Next 5Y10.81%
Revenue 1Y (TTM)12.07%
Revenue growth 3Y9.51%
Revenue growth 5Y8.29%
Sales Q2Q%5.03%
Revenue Next Year4.62%
Revenue Next 2Y5.05%
Revenue Next 3Y5.21%
Revenue Next 5Y5.01%
EBIT growth 1Y23.65%
EBIT growth 3Y10.61%
EBIT growth 5Y16.88%
EBIT Next Year33.24%
EBIT Next 3Y16.88%
EBIT Next 5Y12.32%
FCF growth 1Y7.29%
FCF growth 3Y29.91%
FCF growth 5Y10.8%
OCF growth 1Y46.62%
OCF growth 3Y26.32%
OCF growth 5Y14.75%

VIRBAC SA / VIRP.PA FAQ

What is the ChartMill fundamental rating of VIRBAC SA (VIRP.PA) stock?

ChartMill assigns a fundamental rating of 5 / 10 to VIRP.PA.


What is the valuation status of VIRBAC SA (VIRP.PA) stock?

ChartMill assigns a valuation rating of 4 / 10 to VIRBAC SA (VIRP.PA). This can be considered as Fairly Valued.


Can you provide the profitability details for VIRBAC SA?

VIRBAC SA (VIRP.PA) has a profitability rating of 6 / 10.


Can you provide the financial health for VIRP stock?

The financial health rating of VIRBAC SA (VIRP.PA) is 6 / 10.


Can you provide the expected EPS growth for VIRP stock?

The Earnings per Share (EPS) of VIRBAC SA (VIRP.PA) is expected to grow by 3.92% in the next year.